These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33693561)

  • 21. Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.
    Khoury G; Fromentin R; Solomon A; Hartogensis W; Killian M; Hoh R; Somsouk M; Hunt PW; Girling V; Sinclair E; Bacchetti P; Anderson JL; Hecht FM; Deeks SG; Cameron PU; Chomont N; Lewin SR
    J Infect Dis; 2017 Mar; 215(6):911-919. PubMed ID: 28453847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size.
    Rasmussen TA; Ahuja SK; Kuwanda L; Vjecha MJ; Hudson F; Lal L; Rhodes A; Chang J; Palmer S; Auberson-Munderi P; Mugerwa H; Wood R; Badal-Faesen S; Pillay S; Mngqibisa R; LaRosa A; Hildago J; Petoumenos K; Chiu C; Lutaakome J; Kitonsa J; Kabaswaga E; Pala P; Ganoza C; Fisher K; Chang C; Lewin SR; Wright EJ
    Clin Infect Dis; 2022 Nov; 75(10):1781-1791. PubMed ID: 35396591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.
    Onwumeh J; Okwundu CI; Kredo T
    Cochrane Database Syst Rev; 2017 May; 5(5):CD009818. PubMed ID: 28542796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.
    Gavegnano C; Brehm JH; Dupuy FP; Talla A; Ribeiro SP; Kulpa DA; Cameron C; Santos S; Hurwitz SJ; Marconi VC; Routy JP; Sabbagh L; Schinazi RF; Sékaly RP
    PLoS Pathog; 2017 Dec; 13(12):e1006740. PubMed ID: 29267399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.
    Macatangay BJC; Jackson EK; Abebe KZ; Comer D; Cyktor J; Klamar-Blain C; Borowski L; Gillespie DG; Mellors JW; Rinaldo CR; Riddler SA
    J Infect Dis; 2020 Apr; 221(10):1598-1606. PubMed ID: 31282542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
    Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
    Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Red blood cell distribution width as an easily measurable biomarker of persistent inflammation and T cell dysregulation in antiretrovirally treated HIV-infected adults.
    Zhang Z; Chew GM; Shikuma CM; Gangcuangco LMA; Souza SA; Shiramizu B; Nakamoto BK; Gong T; Mannem SR; Mitchell BI; Kallianpur KJ; Ndhlovu LC; Chow DC
    HIV Clin Trials; 2018 Oct; 19(5):172-176. PubMed ID: 30422099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
    Wilkin TJ; Lalama CM; McKinnon J; Gandhi RT; Lin N; Landay A; Ribaudo H; Fox L; Currier JS; Mellors JW; Gulick R; Tenorio AR
    J Infect Dis; 2012 Aug; 206(4):534-42. PubMed ID: 22740718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
    Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
    Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy.
    Delagreverie HM; Bauduin C; De Castro N; Grinsztejn B; Chevrier M; Jouenne F; Mourah S; Kalidi I; Pilotto JH; Brites C; Tregnago Barcellos N; Amara A; Wittkop L; Molina JM; Delaugerre C
    Open Forum Infect Dis; 2020 Feb; 7(2):ofz549. PubMed ID: 32083147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals.
    Morón-López S; Navarro J; Jimenez M; Rutsaert S; Urrea V; Puertas MC; Torrella A; De Clercq L; Ribas BP; Gálvez C; Salgado M; Vandekerckhove L; Blanco J; Crespo M; Martinez-Picado J
    Clin Infect Dis; 2019 Sep; 69(8):1320-1328. PubMed ID: 30590412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
    Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; Millard KG; Tolstrup M; Jones RB; Conce Alberto WD; Lorenzi JCC; Oliveira TY; Kümmerle T; Suárez I; Unson-O'Brien C; Nogueira L; Olesen R; Østergaard L; Nielsen H; Lehmann C; Nussenzweig MC; Fätkenheuer G; Klein F; Caskey M; Søgaard OS
    Lancet Microbe; 2022 Mar; 3(3):e203-e214. PubMed ID: 35544074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.
    Tebas P; Henry WK; Matining R; Weng-Cherng D; Schmitz J; Valdez H; Jahed N; Myers L; Powderly WG; Katzenstein D
    PLoS One; 2008 Apr; 3(4):e2021. PubMed ID: 18431498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
    Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
    Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS
    J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study).
    Serrano-Villar S; de Lagarde M; Vázquez-Castellanos J; Vallejo A; Bernadino JI; Madrid N; Matarranz M; Díaz-Santiago A; Gutiérrez C; Cabello A; Villar-García J; Blanco JR; Bisbal O; Sainz T; Moya A; Moreno S; Gosalbes MJ; Estrada V
    Clin Infect Dis; 2019 Jan; 68(1):120-130. PubMed ID: 29788075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation.
    Luscombe CA; Avihingsanon A; Supparatpinyo K; Gatechompol S; Han WM; Ewart GD; Thomson AS; Miller M; Becker S; Murphy RL
    J Infect Dis; 2021 Jun; 223(11):1914-1922. PubMed ID: 33038249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.